The DAWN antivirals trial: process evaluation of a COVID-19 trial in general practice.
Dajana TareSamuel CoenenAn De SutterStefan HeytensDirk DevroeyLaetitia BuretSchoenmakers BirgitteNicolas DelvauxJan Yvan Jos VerbakelKris BogaertsAnn van den BruelPublished in: BJGP open (2023)
The DAWN Antivirals trial was stopped prematurely. Although many barriers were related to the pandemic itself, hurdles such as small and inexperienced sponsor and clinical teams, delays in regulatory processes and research capacity in routine settings could be overcome by established research infrastructure and standardization of processes.